Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBT Margin (2017 - 2025)

Neurocrine Biosciences' EBT Margin history spans 15 years, with the latest figure at 29.72% for Q4 2025.

  • For Q4 2025, EBT Margin rose 382.0% year-over-year to 29.72%; the TTM value through Dec 2025 reached 24.66%, up 403.0%, while the annual FY2025 figure was 24.66%, 403.0% up from the prior year.
  • EBT Margin reached 29.72% in Q4 2025 per NBIX's latest filing, down from 36.71% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 209.09% in Q4 2021 to a low of 116.5% in Q2 2022.
  • Average EBT Margin over 5 years is 21.55%, with a median of 23.19% recorded in 2025.
  • Peak YoY movement for EBT Margin: skyrocketed 19227bps in 2021, then plummeted -18047bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 209.09% in 2021, then tumbled by -86bps to 28.62% in 2022, then surged by 34bps to 38.47% in 2023, then crashed by -33bps to 25.9% in 2024, then rose by 15bps to 29.72% in 2025.
  • Per Business Quant, the three most recent readings for NBIX's EBT Margin are 29.72% (Q4 2025), 36.71% (Q3 2025), and 23.2% (Q2 2025).